Identification, study and testing of new remedies for immune imbalance correction in respiratory diseases, particularly bronchial asthma (BA) is of particular interest due to the increased incidence and severity of the disease, which lead to disabilities of working age persons. This highlights the need for development and implementation of new effective and safe medicines from local sources and to meet the priority directions of the development of local science. Of particular interest are sulfated polysaccharides obtained from cyanobacteria Spirulina platensis at the Institute of Microbiology and Biotechnology of the ASM, which were proven to have multiple biological actions on the organism. The purpose of the study was to assess in vitro the peculiarities and significance of interleukin 6 (IL-6) levels changes under the influence of sulfated polysaccharides from spirulina (PSS) in healthy individuals and patients with bronchial asthma (BA) of varying severity. The research was performed on peripheral blood samples collected from 40 patients diagnosed with persistent bronchial asthma (PBA). Patients were divided into the following groups: I – control, that included 10 healthy people; II – 10 patients with mild form of PBA; III – 10 patients with moderate form of PBA; IV – 10 patients with severe form of PBA. All blood samples were treated with PSS. The level of IL-6 was determined by mini-ELISA kit (PeproTech Company, USA). Concentration of proinflammatory cytokine IL-6 in the blood supernatant of the healthy people was 662.9 ± 70.3 pg/ml. Under the influence of PSS in both doses (50 and 100 mg ml) significantly decreases the secretion of cytokine IL-6 by whole blood mononuclear cells in healthy individuals (45%-52% reduction). Incubation of whole blood with PSS in vitro induced significant suppression of the IL-6 production by peripheral blood mononuclear cells of patients with BA. PSS in both dose induced the decrease by 51–52% of IL-6 levels compared to healthy individuals in mild form BA. However, these values were 24–25% lower from the baseline (previous to PSS treatment), but these changes were not statistic relevant. PSS in both dosages statistic significantly reduce the secretion of IL-6 by 48%-61% (p<0.001) in patients with moderate and severe forms of persistent BA compared with the control group values. At the same time, in moderate and severe persistent BA under the influence of PSS occurred an important suppression of the IL-6 production by 71%-74% (p<0.001) and, respectively, by 48%-60% (p<0.01) compared with the initial level. These values were 2 times lower compared to the values specific for healthy people untreated with PSS. The obvious reduction in IL-6 content in moderate and severe persistent BA under the influence of medication with both doses of PSS showed the effectiveness of this remedy in reducing inflammation in allergic diseases. In conclusion, PSS significantly suppressed the proinflammatory mediator IL-6 in mild, moderate and severe forms of BA, which demonstrates the beneficial action of this remedy in BA and confirms the perspectives of its use for treatment of allergic inflammation and immunoregulation of different allergic conditions.